Omeros Corporation

OMER • Biotechnology

$18.95

▼ -0.16 (-0.84%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.70B

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Healthy liquidity · 2.76Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:10 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$18.95

Change-0.84%

Shares Out89.63M

Market Cap$1.70B

Enterprise Value$1.58B

52W Range3.94 - 18.14

Beta2.54

P/E13.61

P/S171.68

P/B-33.08

P/FCF9.92

EV/Sales159.40

Price$18.95

Change-0.84%

Shares Out89.63M

Market Cap$1.70B

Enterprise Value$1.58B

52W Range3.94 - 18.14

Beta2.54

P/E13.61

P/S171.68

P/B-33.08

P/FCF9.92

EV/Sales159.40

EV/EBITDA-21.87

EV/FCF9.21

Earnings Yield7.35%

FCF Yield10.08%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-1.97

Current Ratio2.76

Quick Ratio2.76

Target$33.00

Target Upside74.14%

Target Median$33.00

Target Range33.00 - 33.00

Volume13.36M

Avg Volume1.69M

EPS Surprise0.16

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

50/100

Why this score▼

Healthy liquidity · 2.76Weak profitability

Analyst view

Analyst sentiment and price target

OMER

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

74/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$33.00

Mean

$33.00

Median

$33.00

High

$33.00

Company Overview

IPO: 10/8/2009

Industry: Biotechnology

P/B i: -33.08

Debt / Equity i: -1.97

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: -1.97

Current Ratio: 2.76

Quick Ratio: 2.76

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

Borges David J.

Transaction: 07/22/2026

BUY

Change

+105,000

Price

$9.84

Filing

07/24/2026

Type

BUY

Cancelmo Peter B

Transaction: 07/22/2026

BUY

Change

+105,000

Price

$9.84

Filing

07/24/2026

Type

BUY

Demopulos Gregory A MD

Transaction: 07/22/2026

BUY

Change

+1,000,000

Price

$9.84

Filing

07/24/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Borges David J.	BUY	+105,000	$9.84	07/22/2026	07/24/2026
Cancelmo Peter B	BUY	+105,000	$9.84	07/22/2026	07/24/2026
Demopulos Gregory A MD	BUY	+1,000,000	$9.84	07/22/2026	07/24/2026
Bumol Thomas F.	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Cable Thomas J.	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Demopulos Peter A MD	BUY	+15,000	$10.28	06/18/2026	06/22/2026
HANISH ARNOLD C	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Hood Leroy E. MD PhD	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Perkinson Diana T.	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Shah Rajiv	BUY	+15,000	$10.28	06/18/2026	06/22/2026
Cable Thomas J.	SELL	-7,500	$10.84	05/22/2026	05/27/2026
Cable Thomas J.	SELL	-7,500	$11.61	05/22/2026	05/27/2026
Demopulos Gregory A MD	SELL	-400,000	$10.27	02/18/2026	02/20/2026
Demopulos Gregory A MD	SELL	-357,678	$11.93	02/18/2026	02/20/2026
Borges David J.	SELL	-30,000	$12.31	01/13/2026	01/14/2026
Borges David J.	SELL	-30,000	$3.06	01/13/2026	01/14/2026
Borges David J.	SELL	-30,000	$12.72	01/12/2026	01/14/2026
Demopulos Gregory A MD	BUY	+300,000	Not reported	10/13/2025	10/15/2025
Borges David J.	BUY	+95,000	$3.20	06/30/2025	07/01/2025
Cancelmo Peter B	BUY	+100,000	$3.20	06/30/2025	07/01/2025

About the Company

Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Source - link

Peers

ADCT BCYC FDMT FULC GOSS KALV LXRX NMRA OCGN RAPT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER

BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company's stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end

Defense World

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks Investment Research

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the

Defense World

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	-0.4	-0.24	0.16
2026-03-31	-0.55	3.14	3.69
2025-11-13	-0.58	-0.19	0.39
2025-08-14	-0.55	-0.53	0.02
2025-05-15	-0.57	-0.65	-0.08
2025-03-31	-0.78	-0.63	0.15
2024-11-13	-0.7	-0.64	0.06
2024-08-07	-1.14	-1.12	0.02
2024-05-15	-0.58	-0.74	-0.16
2024-04-01	-0.56	-0.63	-0.07
2023-11-09	-0.62	-0.82	-0.2
2023-08-09	-0.6	-0.7	-0.1